$IRON
Disc Medicine, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023021963 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.230M $4.950M $4.673M
YoY Change 12.38% 5.93% -0.57%
% of Gross Profit
Research & Development $12.10M $20.18M $9.804M
YoY Change 368.99% 105.83% -16.82%
% of Gross Profit
Depreciation & Amortization $20.00K $25.00K $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $17.33M $25.13M $15.18M
YoY Change 139.54% 65.55% -7.96%
Operating Profit -$17.33M -$25.13M -$15.18M
YoY Change 139.54% 65.55% -7.96%
Interest Expense $1.410M $2.370M $66.00K
YoY Change 2837.5% 3490.91% -96.43%
% of Operating Profit
Other Income/Expense, Net $1.405M $2.367M $3.000K
YoY Change 3167.44% 78800.0% -99.57%
Pretax Income -$15.92M -$22.76M -$15.23M
YoY Change 124.58% 49.42% -20.05%
Income Tax $24.00K $23.00K
% Of Pretax Income
Net Earnings -$15.95M -$22.78M -$15.23M
YoY Change 124.92% 49.57% -20.04%
Net Earnings / Revenue
Basic Earnings Per Share -$0.74 -$1.20 -$10.67
Diluted Earnings Per Share -$0.74 -$1.20 -$352.5K
COMMON SHARES
Basic Shares Outstanding 19.80M 19.00M 43.21M
Diluted Shares Outstanding 21.48M 18.95M 923.8K

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $377.6M $236.4M $119.1M
YoY Change 247.51% 98.55% -35.64%
Cash & Equivalents $377.6M $236.4M $119.1M
Short-Term Investments
Other Short-Term Assets $4.100M $5.700M $5.004M
YoY Change -8.28% 13.91% 39.0%
Inventory
Prepaid Expenses $4.131M $5.716M $4.681M
Receivables
Other Receivables
Total Short-Term Assets $381.7M $242.1M $124.1M
YoY Change 237.43% 95.17% -34.22%
LONG-TERM ASSETS
Property, Plant & Equipment $159.0K $180.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $116.0K $116.0K $217.0K
YoY Change -43.14% -46.54% -3.56%
Total Long-Term Assets $2.441M $1.642M $217.0K
YoY Change 1096.57% 656.68% -72.07%
TOTAL ASSETS
Total Short-Term Assets $381.7M $242.1M $124.1M
Total Long-Term Assets $2.441M $1.642M $217.0K
Total Assets $384.2M $243.8M $124.3M
YoY Change 238.98% 96.15% -34.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.214M $5.642M $5.110M
YoY Change 222.25% 10.41% 43.46%
Accrued Expenses $4.148M $4.025M $3.405M
YoY Change 117.74% 18.21% -34.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.159M
YoY Change -16.82%
Total Short-Term Liabilities $9.683M $9.980M $12.67M
YoY Change 50.45% -21.26% -8.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $3.300M $900.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $3.300M $900.0K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.683M $9.980M $12.67M
Total Long-Term Liabilities $3.300M $900.0K $0.00
Total Liabilities $12.96M $10.93M $12.67M
YoY Change 101.29% -13.8% -30.44%
SHAREHOLDERS EQUITY
Retained Earnings -$150.9M -$135.0M -$199.9M
YoY Change -27.11% -32.47% 51.61%
Common Stock $2.000K $2.000K $4.000K
YoY Change -50.0% -50.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $371.2M $232.9M $111.6M
YoY Change
Total Liabilities & Shareholders Equity $384.2M $243.8M $124.3M
YoY Change 238.98% 96.15% -34.37%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$15.95M -$22.78M -$15.23M
YoY Change 124.92% 49.57% -20.04%
Depreciation, Depletion And Amortization $20.00K $25.00K $0.00
YoY Change -100.0%
Cash From Operating Activities -$12.72M -$35.47M -$16.34M
YoY Change 33.92% 117.08% 8.87%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $29.00K $100.0K
YoY Change -71.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$29.00K -$100.0K
YoY Change -71.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 153.9M 77.31M -1.225M
YoY Change -12608.13% -6410.69% -100.63%
NET CHANGE
Cash From Operating Activities -12.72M -35.47M -16.34M
Cash From Investing Activities -10.00K -29.00K -100.0K
Cash From Financing Activities 153.9M 77.31M -1.225M
Net Change In Cash 141.1M 41.81M -17.56M
YoY Change -1415.44% -338.06% -109.73%
FREE CASH FLOW
Cash From Operating Activities -$12.72M -$35.47M -$16.34M
Capital Expenditures $10.00K $29.00K $100.0K
Free Cash Flow -$12.73M -$35.50M -$16.44M
YoY Change 115.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#DerivativeGainLossOnDerivativeNet
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001816736
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39438
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Disc Medicine, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3220679
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
321 Arsenal Street, Suite 101
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2023Q1 dei City Area Code
CityAreaCode
617
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
674-9274
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value
CY2023Q1 dei Trading Symbol
TradingSymbol
IRON
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19799357
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
236422000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
194611000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5716000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3880000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
242138000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
198491000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
180000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
168000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1346000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1430000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
116000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
116000
CY2023Q1 us-gaap Assets
Assets
243780000
CY2022Q4 us-gaap Assets
Assets
200205000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5642000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16162000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4025000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6109000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
313000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
307000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9980000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22578000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
945000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1027000
CY2023Q1 us-gaap Liabilities
Liabilities
10925000
CY2022Q4 us-gaap Liabilities
Liabilities
23605000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19576200
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17405231
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19575242
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17403315
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
367850000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
288814000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134997000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112216000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
232855000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
176600000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
243780000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
200205000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20180000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7821000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4945000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2139000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
25125000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
9960000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-25125000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9960000
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
2367000
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
7000
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
100000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2367000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
107000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22758000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9853000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22781000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9853000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22781000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-22781000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9853000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9853000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18954914
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18954914
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
923750
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
923750
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.20
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.20
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.67
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.67
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-64203000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55000
CY2022Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
332000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9853000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-73669000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
176600000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41811000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13746000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
194788000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1067000
CY2023Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1024000
CY2023Q1 iron Common Stock In Registered Direct Offering Net Of Issuance Costs
CommonStockInRegisteredDirectOfferingNetOfIssuanceCosts
80000
CY2023Q1 iron Stock Issued During Period Value Sale Of Common Stock In Registered Direct Offering
StockIssuedDuringPeriodValueSaleOfCommonStockInRegisteredDirectOffering
34148000
CY2023Q1 iron Pre Funded Warrants In Registered Direct Offering Net Of Issuance Costs
PreFundedWarrantsInRegisteredDirectOfferingNetOfIssuanceCosts
66000
CY2023Q1 iron Stock Issued During Period Value Sale Of Pre Funded Warrants In Registered Direct Offering
StockIssuedDuringPeriodValueSaleOfPreFundedWarrantsInRegisteredDirectOffering
28206000
CY2023Q1 iron Common Stock In At The Market Offerings Net Of Issuance Costs
CommonStockInAtTheMarketOfferingsNetOfIssuanceCosts
408000
CY2023Q1 iron Stock Issued During Period Value Sale Of Common Stock In At The Market Offerings
StockIssuedDuringPeriodValueSaleOfCommonStockInAtTheMarketOfferings
14591000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22781000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
232855000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-22781000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-9853000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
18000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1024000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
332000
CY2023Q1 iron Change In Fairv Alue Of Derivative
ChangeInFairvAlueOfDerivative
0
CY2022Q1 iron Change In Fairv Alue Of Derivative
ChangeInFairvAlueOfDerivative
100000
CY2023Q1 iron Noncash Lease Expense
NoncashLeaseExpense
84000
CY2022Q1 iron Noncash Lease Expense
NoncashLeaseExpense
74000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
908000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3195000
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
64000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10750000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-982000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2084000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-18000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-76000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-77000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35466000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13701000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
100000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-100000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34217000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2023Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
28262000
CY2022Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
CY2023Q1 us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
14605000
CY2022Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
222000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
55000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77306000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88213000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
236599000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74467000
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
11000
CY2023Q1 iron Receivable For Proceeds From Stock Option Exercises Included In Other Current Assets1
ReceivableForProceedsFromStockOptionExercisesIncludedInOtherCurrentAssets1
845000
CY2022Q1 iron Receivable For Proceeds From Stock Option Exercises Included In Other Current Assets1
ReceivableForProceedsFromStockOptionExercisesIncludedInOtherCurrentAssets1
0
CY2023Q1 iron Deferred Issuance Costs On Sale Of Common Stock In Registered Direct Offering Included In Accounts Payable And Accrued Expenses1
DeferredIssuanceCostsOnSaleOfCommonStockInRegisteredDirectOfferingIncludedInAccountsPayableAndAccruedExpenses1
69000
CY2022Q1 iron Deferred Issuance Costs On Sale Of Common Stock In Registered Direct Offering Included In Accounts Payable And Accrued Expenses1
DeferredIssuanceCostsOnSaleOfCommonStockInRegisteredDirectOfferingIncludedInAccountsPayableAndAccruedExpenses1
0
CY2023Q1 iron Deferred Issuance Costs On Sale Of Pre Funded Warrants In Registered Direct Offering Included In Accounts Payable And Accrued Expenses
DeferredIssuanceCostsOnSaleOfPreFundedWarrantsInRegisteredDirectOfferingIncludedInAccountsPayableAndAccruedExpenses
56000
CY2022Q1 iron Deferred Issuance Costs On Sale Of Pre Funded Warrants In Registered Direct Offering Included In Accounts Payable And Accrued Expenses
DeferredIssuanceCostsOnSaleOfPreFundedWarrantsInRegisteredDirectOfferingIncludedInAccountsPayableAndAccruedExpenses
0
CY2023Q1 iron Deferred Issuance Costs On Sale Of Common Stock In At The Market Offerings Included In Accounts Payable And Accrued Expenses
DeferredIssuanceCostsOnSaleOfCommonStockInAtTheMarketOfferingsIncludedInAccountsPayableAndAccruedExpenses
97000
CY2022Q1 iron Deferred Issuance Costs On Sale Of Common Stock In At The Market Offerings Included In Accounts Payable And Accrued Expenses
DeferredIssuanceCostsOnSaleOfCommonStockInAtTheMarketOfferingsIncludedInAccountsPayableAndAccruedExpenses
0
CY2023Q1 iron Deferred Issuance Costs On Equity Financing Included In Accounts Payable And Accrued Expenses
DeferredIssuanceCostsOnEquityFinancingIncludedInAccountsPayableAndAccruedExpenses
0
CY2022Q1 iron Deferred Issuance Costs On Equity Financing Included In Accounts Payable And Accrued Expenses
DeferredIssuanceCostsOnEquityFinancingIncludedInAccountsPayableAndAccruedExpenses
384000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
236400000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135000000.0
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to accrued research and development expenses; stock-based compensation expense; the fair value of the common stock prior to the effective date of the merger; the fair value determinations for instruments accounted for at fair value including contingent amounts payable to third parties upon the consummation of specified transactions, including a Roche Qualified Transaction (see Note 8); the fair value of Gemini’s development programs underlying the CVR; the incremental borrowing rate for determining lease liabilities and right-of-use assets and income taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it has concluded to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">period in which they become known. Actual results may differ materially from those estimates or assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and of Significant Suppliers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to cash risk by placing its cash with high credit quality accredited financial institutions. The Company has concluded that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and to process its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the manufacturing process or supply chain.</span></p>
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
236422000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
194611000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
177000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
177000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
236599000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
194788000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
170000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
145000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
180000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
168000
CY2023Q1 iron Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
2457000
CY2022Q4 iron Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
1817000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
876000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3623000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
347000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
463000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
345000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
206000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4025000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6109000
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 iron Common Stock Authorized And Reserved For Future Issuance
CommonStockAuthorizedAndReservedForFutureIssuance
2527513
CY2023Q1 iron Stock Reserved During Period Shares Exercise Of Prefunded Warrants
StockReservedDuringPeriodSharesExerciseOfPrefundedWarrants
1229224
CY2023Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
100000000.0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2640590
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.19
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y29D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
25513000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
25756
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
23.10
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
74753
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
15.04
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
64080
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
99.98
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2527513
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.17
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M19D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28068000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1022728
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.21
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M2D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
13318000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
500000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0386
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0182
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.62
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.56
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Price
SharePrice
23.10
CY2022Q1 us-gaap Share Price
SharePrice
14.69
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.06
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.85
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
800000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1916
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
10170
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
958
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
2285
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
958
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7885
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1024000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
332000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
9300000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M13D
CY2023Q1 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2022Q1 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2023Q1 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
100000
CY2022Q1 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2023Q1 iron Exercise Of Pre Funded Warrants Shares
ExerciseOfPreFundedWarrantsShares
0
CY2023Q1 iron Pre Funded Warrants Outstanding
PreFundedWarrantsOutstanding
1229224
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000
CY2023Q1 iron Short Term Bank Loans And Notespayable Percentage
ShortTermBankLoansAndNotespayablePercentage
0.045

Files In Submission

Name View Source Status
0000950170-23-021963-index-headers.html Edgar Link pending
0000950170-23-021963-index.html Edgar Link pending
0000950170-23-021963.txt Edgar Link pending
0000950170-23-021963-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
iron-20230331.htm Edgar Link pending
iron-20230331.xsd Edgar Link pending
iron-ex10_1.htm Edgar Link pending
iron-ex31_1.htm Edgar Link pending
iron-ex31_2.htm Edgar Link pending
iron-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
iron-20230331_def.xml Edgar Link unprocessable
iron-20230331_lab.xml Edgar Link unprocessable
iron-20230331_cal.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
iron-20230331_pre.xml Edgar Link unprocessable
iron-20230331_htm.xml Edgar Link completed